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Human immunodeﬁciency virus (HIV)-infected patients have an im-
proved life expectancy thanks to highly active antiretroviral therapies
(HAART). The incidences of opportunistic infections and AIDS-deﬁning
cancers (ADCs) such as Kaposi sarcoma and non-Hodgkin lymphoma,
have markedly decreased. However, the incidences of non-AIDS-
deﬁning cancers (NADCs) such as Hodgkin lymphoma, anal carcinoma,
lung cancer, hepatocellular carcinoma (HCC), and head and neck can-
cers have been steadily increasing over the past two decades [1–4].
HIV+ patients are known to have increased risk for developing
NADCs, even when adjusted for known cancer risk factors. In fact,
NADCs are a major cause of death of HIV+ patients in the HAART era.
The overall relative risk for all NADCs is about two fold higher than in
the general population, adjusted for age and gender. Risk estimates
vary substantially, per cancer type, anatomic sites, study period, and re-
gion. Additionally, outcome for HIV+ patients with NADCs is much
poorer compared to HIV-negative counterparts. The reasons for these
ﬁndings in HIV-infected patients are not understood and pose chal-
lenges on their clinicalmanagement. Likely, viral-mediated oncogenesis
plays a greater role in HIV+ NADCs, compared to the general popula-
tion and viral causation is well-established with many NADCs.
Epstein-Barr virus (EBV) is a known promoter of ADCs (non-Hodgkin
lymphoma) and NADCs (Hodgkin lymphoma, nasopharyngeal carcino-
ma, Burkitt's lymphoma) [5,6]. HumanHerpes Virus 8 is associatedwith
Kaposi sarcoma and primary effusion lymphoma [7]. Hepatitis C and B
viruses are associated with hepatocellular carcinoma [8]. High-risk
Human Papillomavirus is responsible for mediating carcinogenesis of
the cervix, anus, and oropharynx [9].
The incidence of conjunctival squamous carcinoma (also referred to
as ocular surface carcinomas), another NADC, has dramatically in-
creased in HIV infected patients [10,11]. Conventional conjunctival
squamous carcinoma is usually an indolent malignancy of older men
[12]. In contrast, HIV+ conjunctival squamous carcinomas occur in
younger patients, are diagnosed at more advanced stage, and associated
with poorer prognoses than the conventional counterparts [13–16].
Emerging publications have established a variable association between
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carcinoma in HIV+ female who experienced rapid tumor progression.
2. Case report
A46-year-old Caucasianwoman tested positive forHIV andhepatitis
C virus in July of 2003. She was noncompliant with standard antiretro-
viral agents. Her initial CD4 cell absolute count was 232 cells/mm [3].
The most recent CD4 absolute count, two months prior to diagnosis,
was 80 cells/mm3. She noted a lesion of the right upper palpebral con-
junctiva, which was biopsied and diagnosed as poorly differentiated
squamous cell carcinoma.
She underwent resection of the right upper eyelid, with reconstruc-
tion involving rotation of the lower lid to replace the upper lid. The car-
cinoma was 2.5 cm in greatest dimension with a thickness of 7 mm. It
involved the entire palpebral conjunctiva extending down to the free
eyelid edge, and up to the superior fornix. Microscopically, the poorly
differentiated squamous cell carcinoma demonstrated spindle cell
(sarcomatoid) features (Fig. 1). Solid and vague papillary architecture
was seen. Central necrosis was present in the solid areas. Carcinoma in-
vaded palpebral musculature with a pushing, transitional-like, nonag-
gressive pattern of invasion. The tumor was nonkeratinizing and
basaloid; tumor cells had scant pink cytoplasm, pleomorphic
hyperchromatic nuclei and inconspicuous nucleoli. Some areas showed
prominent elongated nuclei with spindle cell changes. There were nu-
merousmitoses, up to 23/HPF. No overt keratin production or glandular
differentiationwere present. Nomultinucleated tumor giant cells or an-
aplastic cells were seen. In-situ carcinoma extended to the medial con-
junctival margin.
Disease recurrencewas evident after fourmonths. Clinically, a poor-
ly demarcated, white-pink, retracted mucosal lesion was present close
to the medial canthus adjacent to the previous rotated resection site
(Fig. 2). Orbital exenteration with reconstruction was performed six
months after the ﬁrst resection, with intention of cure.Microscopic con-
junctival carcinoma was present adjacent to prior surgical site with a
nonaggressive, pushing pattern of invasion (Fig. 2). Themedial canthus,
lacrimal sac, and globe were uninvolved. The closest resection margin
was 4 mm. Currently, she is disease-free after four months after salvage
surgery.
Immunohistochemistry revealed tumor expression of p63 and CK5/
6. p16 was overexpressed with a strong, diffuse, nuclear and cytoplas-
mic pattern (Fig. 3A). HPV in-situ hybridization using commercially
available probes recognizing HPV genotypes 6/11, 16/18, 31/33 wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1.A, B, C: Low and high-power views of in-situ and inﬁltrating basaloid squamous carcinoma of palpebral conjunctiva. D:Higher power revealing a basaloid squamous carcinomawith
palisading and evidence of maturation. No keratin pearls or multinucleated/anaplastic tumor cells were present.
2 J. Sun et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxpositive forHR-HPV16/18. (Fig. 3B). No signalswere seen forHPV31/33
or 6/11. EBER in-situ hybridization was negative. Immunohistochemis-
try for HHV-8 was negative.3. Discussion
Conjunctival squamous carcinoma, also referred to as ocular surface
squamous neoplasia, commonly present as a ﬂeshy, gelatinous, papillo-
matous or sessile lesion in the interpalpebral area of perilimbal conjunc-
tiva. Generally, associated risk factors are HIV, immune suppression
fromother causes, ultraviolet B radiation exposure, chemicals, ocular in-
jury, and vitamin A deﬁciency. Two distinct biological and demographic
patterns emerge for this cancer. Conventional conjunctival squamous
carcinoma is rare, indolent, and seenmostly inmiddle agedmales living
in high-latitude regions[12,22,23]. This entity is characterized by slow
growth and good outcome. Complete surgical excision with margin
clearance is effective; the rates of local recurrence and regionalmetasta-
ses are low [12,22,23].Please cite this article as: J. Sun, et al., Conjunctival squamous carcinoma in
Human Path Case Reports (2016), http://dx.doi.org/10.1016/j.ehpc.2016.0The second pattern involves younger individuals with no gender
predilection who live in equatorial Africa; this group is also likely to
be HIV+ [10]. The upsurge of HIV infection and NARCs highlights
these changing trends. Overall, conjunctival squamous carcinoma is
rare in the United States; the U.S. HIV/AIDS Cancer Match Registry
Study (1980 to 2004) contains 15 conjunctival squamous carcinomas,
representing a signiﬁcant increase [13]. Shields et al. report that HIV+
conjunctival carcinomas are clinically more aggressive and require enu-
cleation or exenteration [14]. For example, a 38-year-old Thai HIV+ fe-
male sought medical attention 3 months noticing a tumor, which was
aggressive enough to cause blindness requiring exenteration [16].
The inherent immunosuppression of HIV infection facilitates the
other oncoviruses which initiate or promote carcinogenesis.
Coinfections with HPV, EBV and HHV-8, are responsible for the large
number of ADCs andNADCs inHIV+persons. The associations between
HIV and HPV infections in general and in the context of cervical neopla-
sia, are well established [24]. There are only a few studies on head and
neck squamous cell carcinoma in the high-risk population of HIV pa-
tients [25,26].an HIV+woman: Association with high-risk human papillomavirus,
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Fig. 2. A. Orbital exenteration: the upper lid had been previously resected and the lower lid was rotated and used to replace the upper lid. Region A (yellow), medial, represents the site of
tumor recurrence appearing retracted. The cornea is cloudy due to edema. The red/pink region (B) (yellow) represents exposed, edematous conjunctiva and sclera. B and C represent dis-
ease recurrence. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
3J. Sun et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxConjunctival/lacrimal squamous carcinomas have been variably as-
sociated with HPV, both in the general population and subset of HIV+
patients. Just recently, HPV16 was demonstrated in a high proportionFig. 3. A: p16 overexpression. B: In-situ hybridization for HR-HPV 16/18 reveals nuclear signals
the reader is referred to the web version of this article.)
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theUS, in a group of predominantly HIV-negative patients [17]. Of inter-
est, the HPV+ invasive cancers more likely resembled HPV-mediated(brown) in tumor cells. (For interpretation of the references to colour in this ﬁgure legend,
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4 J. Sun et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxoropharyngeal cancers (nonkeratinizing, or partially keratinizing), as is
illustrated in this case. This ﬁndingwould then be a rationale for pathol-
ogists to test basaloid, nonkeratinizing, or partially keratinizing ocular
surface squamous carcinomas, especially in patients under 50 years.
Squamous carcinoma represents the most common form of ocular
surface neoplasia [27–31]. Precursors (conjunctival intraepithelial neo-
plasia) can manifest various appearances and clinically present as leu-
koplakic, nodular, pigmented, vascular, papillary, or ﬂeshy lesions.
Microscopically, the spectrum of precursors are classiﬁed as either
mild-, moderate-, or severe- dysplasia/carcinoma in-situ (CIS). This rep-
resents somewhat of a departure from grading oral dysplasias. In the
oral cavity, the tendency is to avoid “moderate dysplasia” as a diagnostic
category, thus ﬂattening the classiﬁcation to low-grade versus high-
grade dysplasia/CIS. Ocular surface low-grade dysplasia is characterized
by disorganized maturation, binucleated epithelial cells, and some de-
gree of nuclear atypia. Moderate dysplasia is characterized by a greater
degree of disorganization and cytologic pleomorphism involving at least
the lower half of the thin ocular surface epithelium. Mitotic ﬁgures may
also be seen. Severe dysplasia/CIS is characterized by yet a greater de-
gree of disorganization and cytologic pleomorphism which spans be-
yond the lower half of the thin surface epithelium. The basement
membrane is intact and no invasion is present.
As mentioned, conventional squamous cell carcinoma (SCC) repre-
sents the most common form of ocular surface neoplasia, which can
be either nonkeratinizing and basaloid (as this case) or keratinizing. A
number of SCC variants may also be seen such as acantholytic or
adenoidsquamous variant (producing pseudoglands due to
discohesiveness) [32], lymphoepithelial variant, sarcomatoid or spindle
cell variant SCC, and mucoepidermoid carcinoma (MEC). The latter is
another interesting departure from the upper aerodigestive tract, as
here MEC is classiﬁed as minor salivary in origin, although it may arise
from surface mucosa. Conjunctival mucosa does not contain any sub-
mucosal seromucinous glands, rather the mucosa itself has mucinous
(goblet cell) differentiation. Ocular surface MEC, and the sarcomatopid
and pseudoglandular variants are noteworthy in that they tend towards
greater aggressiveness than conventional carcinoma.
A Ugandan study of conjunctival carcinomas (79 HIV+, 15 HIV neg-
ative) and precursors (34 HIV+, 5 HIV negative) interrogated bothmu-
cosal and cutaneous (β genus) HPV types [18]. Interestingly, cutaneous
HPV types (most often HPV5 and HPV8) were signiﬁcantly more com-
mon in cancers and precursors, especially among HIV+ patients; infec-
tion with multiple HPV types was common [18]. Not all conjunctival
carcinoma studies ﬁnd evidence of HPV; this might reﬂect geographic
differences, sensitivity of detection methods, or simply the fact that no
β genus HPV types were queried [33–35]. Of note, HHV-8 has been de-
tected in 12/48 (25%)HIV+Ugandanswith conjunctival squamous car-
cinoma by PCR [36].
A recently publishedmeta-analysis based on large study series com-
mencing in the late 1980's conﬁrmed a strong association between HIV
and risk of ocular surface squamous neoplasia (RR 8.06, 95% CI:
5.29–12.30) [37]. The increased relative risk associated with mucosal
HPV was 3.13 (95% CI: 1.72–5.71). Studies which addressed any associ-
ation between both cutaneous and mucosal HPV and ocular surface
squamous neoplasia demonstrated a stronger relationship with cutane-
ous HPV (RR 3.52, 95% CI: 1.23–10.08) compared to mucosal HPV (RR
1.08, 95% CI: 0.57–2.05).
It is well-established that outcomes for p16+/HPV mediated oro-
pharyngeal cancers in the general population is improved as compared
to p16-/HPV-counterparts [38]. Enhanced adaptive immunity to HPV is
one of the factors responsible for this survival beneﬁt [39–43]. On the
other hand, NADCs are associated with worse outcomes compared to
the general population, likely reﬂecting decreased immune status. We
conclude that the current tumor is mediated by HPV16/18. Future stud-
ies of HIV+ conjunctival/lacrimal sac carcinomas should also query and
validate the presence of β genus HPV and HHV-8.Please cite this article as: J. Sun, et al., Conjunctival squamous carcinoma in
Human Path Case Reports (2016), http://dx.doi.org/10.1016/j.ehpc.2016.0References
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